高级检索
当前位置: 首页 > 详情页

Circular RNA circEIF4G2 aggravates renal fibrosis in diabetic nephropathy by sponging miR-218.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Endocrinology, Tongren Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China
出处:
ISSN:

关键词: circEIF4G2 diabetic nephropathy miR-218 SERBP1

摘要:
Circular RNAs play essential roles in the development of various human diseases. However, how circRNAs are involved in diabetic nephropathy (DN) are not fully understood. Our study aimed to investigate the effects of circRNA circEIF4G2 on DN. Experiments were performed in the db/db mouse model of type 2 diabetes and NRK-52E cells. We found that circEIF4G2 was significantly up-regulated in the kidneys of db/db mice and NRK-52E cells stimulated by high glucose. circEIF4G2 knockdown inhibited the expressions of TGF-β1, Collagen I and Fibronectin in high glucose-stimulated NRK-52E cells, which could be rescued by miR-218 inhibitor. Knockdown of SERBP1 reduced the expression of TGF-β1, Collagen I and Fibronectin in HG-stimulated NRK-52E cells. In summary, our findings suggested that circEIF4G2 promotes renal tubular epithelial cell fibrosis via the miR-218/SERBP1 pathway, presenting a novel insight for DN treatment.© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验 3 区 细胞生物学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 细胞生物学 3 区 医学:研究与实验
第一作者:
第一作者机构: [1]Department of Endocrinology, Tongren Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Endocrinology, Tongren Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China [*1]Department of Endocrinology, Tongren Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:25463 今日访问量:0 总访问量:1498 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)